Navigation Links
Promising new finding for therapies to treat persistent seizures in epileptic patients
Date:1/16/2013

LOS ANGELES (Jan. 16, 2013) In a promising finding for epileptic patients suffering from persistent seizures known as status epilepticus, researchers reported today that new medication could help halt these devastating seizures. To do so, it would have to work directly to antagonize NMDA receptors, the predominant molecular device for controlling synaptic activity and memory function in the brain.

"Despite the development of new medications to prevent seizures, status epilepticus remains a life-threatening condition that can cause extensive brain damage in the patients that survive these persistent seizures," said David E. Naylor, MD, PhD, a lead researcher at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) and corresponding author of the new study. "Our research holds promise for the development of new therapies to treat this devastating condition because we have found a potential new target for medical intervention that should bolster the current standard therapies to treat the acute seizures. It may also prevent the long-term adverse effects of persistent seizure activity on the brain."

The research, reported online in the Neurology of Disease journal, used animal models to assess cellular activity in the brain during persistent seizures. It found that the seizure activity seemed to force the NMDA receptors from the interior to the surface of nerve cells causing their activity to increase by approximately 38%.

"The increased presence of the NMDA receptors on the cell surface during these seizures may explain the successful use of NMDA antagonists medication that inhibits the activity of the NMDA receptors in the brain in the latter stages of a seizure, long after other medications have stopped working," said Dr. Naylor. "We concluded that medications that suppress the activity of the NMDA receptors, in conjunction with other medications, may be successful in stopping persisten
'/>"/>

Contact: Laura Mecoy
lmecoy@labiomed.org
310-546-5860
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Promising compound restores memory loss and reverses symptoms of Alzheimers
2. Stanford geoscientist cites critical need for basic research to unleash promising energy sources
3. Alzheimers disease in mice alleviated promising therapeutic approach for humans
4. Stem cells + nanofibers = Promising nerve research
5. Berkeley Lab scientists help develop promising therapy for Huntingtons disease
6. Promising new drug target for inflammatory lung diseases
7. Space research institute awards funding to promising medical products
8. American Health Assistance Foundation announces grants to advance promising vision research
9. 22 of Americas most promising scientists selected as Pew Biomedical Scholars
10. UH Case Medical Center, CardioKinetix reveal promising data for treatment for heart failure
11. Ultrasensitive biosensor promising for medical diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Promising new finding for therapies to  treat persistent seizures in epileptic patients
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
(Date:5/14/2015)... , May 14, 2015  Verificient Technologies, ... verification and online remote proctoring, announced a ... (SaaS) company and creator of the Canvas ... the two companies will benefit from the ... As a fully integrated multifactor ...
(Date:5/11/2015)... May 11, 2015 Curemark LLC, a privately ... of a new Phase III double blind, randomized, placebo-controlled ... formulation, CM-AT, on all children ages 3-8 with Autism. ... Phase III double blinded clinical trial for CM-AT in ... of the digestive enzyme chymotrypsin. This new trial will ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... a world-leading provider of scientific, technical and medical information products ... by the European Menopause and Andropause Society (EMAS) in journal ... postmenopausal women with summary recommendations. Vitamin D deficiency is ... is classified as a public health issue as it can ...
... billion-dollar-a-year industry in the United States that aims to create ... But a new analysis of restoration projects shows that restored ... "Once you degrade a wetland, it doesn,t recover its normal ... carbon, which both affect natural cycles of water and nutrients, ...
... hydrothermal sea vents go dormant and their blistering warmth turns to ... replaced. A team led by USC microbiologist Katrina Edwards found ... spewed by active hydrothermal vents are supplanted, once the vents go ... that make up the vents themselves. These findings based ...
Cached Biology News:Elsevier's Maturitas publishes position statement on the role of vitamin D in postmenopausal women 2Restored wetlands rarely equal condition of original wetlands 2Restored wetlands rarely equal condition of original wetlands 3Life discovered on dead hydrothermal vents 2
(Date:5/21/2015)... , May 21, 2015  The EveryLife ... Hatch (R-UT) and Amy Klobuchar ... Now Accelerating Cures & Treatments, or OPEN ACT. ... disease patient advocacy organizations, this bipartisan legislation promises ... affordable medicines to rare disease patients by incentivizing ...
(Date:5/21/2015)... 2015 As part of its philanthropic ... Sun Health Foundation funded a $3.25 million project to ... with the most up-to-date features and technology. , The ... pharmacy's 45 staff members will begin moving from the ... the coming days. , The current pharmacy has ...
(Date:5/20/2015)... Calif. , May 20, 2015 ... today presented preliminary data demonstrating the ability of ... pulmonary fibrosis (IPF) from other interstitial lung diseases ... suggest the classifier,s potential to help thousands of ... resolve ambiguity in IPF diagnosis – a frequent ...
(Date:5/20/2015)... 2015 The global genotyping market is ... the forecast period of 2015 to 2020 to reach ... in drug discovery and development process and to provide ... addition to this,heavy investments by key manufacturers to offer ... propelling market growth. Browse 113 market data tables & ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5
... chemists have developed a new model to predict the ... finding could help inform the design of tailored nano-structures, ... fields, including the remote sensing of atmospheric pollutants and ... nano-particles play a key role in atmospheric processes as ...
... Biotechnology, Inc. (OTC: CSBR) ("Champions") announced today the ... Inc. in which Champions will conduct low passage ... an inhibitor of mutant B-Raf, and CEP-37440, a ... determine the activity or response in potential clinical ...
... Health Diagnostic Laboratory, Inc. (HDL, Inc.) and BG Medicine, Inc. ... which HDL, Inc. will offer galectin-3 testing services based on ... Medicine Galectin-3 Test was recently cleared by the FDA as ... heart failure. Elevated galectin-3 levels are associated with an inherently ...
Cached Biology Technology:UBC researchers develop new model to predict the optical properties of nano-structures 2Champions Announces Technology Collaboration Utilizing Champions' Tumorgraft™ Technology Platform for Oncology Drug Development 2Champions Announces Technology Collaboration Utilizing Champions' Tumorgraft™ Technology Platform for Oncology Drug Development 3Health Diagnostic Laboratory, Inc. (HDL, Inc.) Announces Availability of Galectin-3 Testing Service in Partnership With BG Medicine 2Health Diagnostic Laboratory, Inc. (HDL, Inc.) Announces Availability of Galectin-3 Testing Service in Partnership With BG Medicine 3Health Diagnostic Laboratory, Inc. (HDL, Inc.) Announces Availability of Galectin-3 Testing Service in Partnership With BG Medicine 4
... media are rigid macroporous hydrophilic media. The ... at moderate pressures, while the macroporous beads ... hydrophilic matrix reduces nonspecific binding. Macro-Prep High ... exchanger with very high flow rates and ...
... collection of phage display libraries, human ... and mouse tissues. All cDNA libraries ... size of cDNA inserts has been ... 1000bp by gel electrophoresis of DNA ...
... Corticosterone kit is a competitive enzymeimmunoassay (EIA) ... mouse or rat serum or plasma. Corticosterone ... in rats and mice, and in most ... reptiles. Most mammals produce both corticosterone and ...
Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
Biology Products: